Cargando…

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients

BACKGROUND: Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment. METHODS: Sixty children recruited to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campanilho-Marques, Raquel, Deakin, Claire T., Simou, Stefania, Papadopoulou, Charalampia, Wedderburn, Lucy R., Pilkington, Clarissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161150/ https://www.ncbi.nlm.nih.gov/pubmed/32293539 http://dx.doi.org/10.1186/s13075-020-02164-5

Ejemplares similares

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling
por: Deakin, Claire T., et al.
Publicado: (2018)

Clinically inactive disease in juvenile dermatomyositis – a proposed revision to the printo criteria
por: Almeida, Beverley, et al.
Publicado: (2014)

Comparison of the utility and validity of three scoring tools to detect skin disease in patients with juvenile dermatomyositis
por: Campanilho-Marques, Raquel, et al.
Publicado: (2014)

Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models
por: Deakin, Claire T, et al.
Publicado: (2020)

The Vasculopathy of Juvenile Dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2018)

Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM)
por: McCann, Liza J, et al.
Publicado: (2011)

Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools
por: Wienke, Judith, et al.
Publicado: (2018)

OA29 Blotting-based assays under-detected TIF1-gamma and NXP2 autoantibodies compared to immunoprecipitation in Juvenile Dermatomyositis cohorts
por: Nguyen, Huong D, et al.
Publicado: (2022)

Tubuloreticular inclusions in juvenile dermatomyositis: a diagnostically useful marker?
por: Yasin, Shireena A, et al.
Publicado: (2014)

A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies
por: Martin, Neil, et al.
Publicado: (2011)

Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective
por: Boros, C., et al.
Publicado: (2022)

Sub-phenotyping of juvenile dermatomyositis: can it assist clinical decisions?
por: Yasin, Shireena A, et al.
Publicado: (2014)

Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
por: Wilkinson, Meredyth G Ll, et al.
Publicado: (2023)

Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated
por: Almeida, Beverley, et al.
Publicado: (2015)

Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2018)

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2019)

Comparison of Children With Onset of Juvenile Dermatomyositis Symptoms Before or After Their Fifth Birthday in a UK and Ireland Juvenile Dermatomyositis Cohort Study
por: Martin, N, et al.
Publicado: (2012)

Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use
por: McCann, Liza J., et al.
Publicado: (2015)

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis
por: Campanilho‐Marques, Raquel, et al.
Publicado: (2016)

Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research
por: McCann, Liza J, et al.
Publicado: (2014)

JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology
por: Ll Wilkinson, Meredyth G., et al.
Publicado: (2021)

Consensus-based recommendations for the management of juvenile dermatomyositis
por: Enders, Felicitas Bellutti, et al.
Publicado: (2017)

Being on the juvenile dermatomyositis rollercoaster: a qualitative study
por: Livermore, Polly, et al.
Publicado: (2019)

Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care
por: Papadopoulou, Charalampia, et al.
Publicado: (2023)

Maternal microchimerism in muscle biopsies from children with juvenile dermatomyositis
por: Ye, Yi, et al.
Publicado: (2012)

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study
por: Tansley, Sarah L, et al.
Publicado: (2014)

Regulatory B cell Il-10 production is diminished in juvenile dermatomyositis
por: Piper, Christopher, et al.
Publicado: (2014)

Mapping the current psychology provision for children and young people with juvenile dermatomyositis
por: Livermore, Polly, et al.
Publicado: (2021)

SHARE – workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile dermatomyositis
por: Enders, Felicitas Bellutti, et al.
Publicado: (2014)

PReS-FINAL-2130-A: Effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis - a national cohort study UK and Ireland
por: Moraitis, E, et al.
Publicado: (2013)

Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?
por: Tansley, Sarah L, et al.
Publicado: (2013)

Juvenile Dermatomyositis
por: Rhim, Jung Woo
Publicado: (2022)

Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis
por: Nistala, Kiran, et al.
Publicado: (2013)

Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis
por: Deakin, Claire T, et al.
Publicado: (2022)

Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
por: McCann, Liza J, et al.
Publicado: (2018)

Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features
por: Yasin, S. A., et al.
Publicado: (2019)

Expression of myxovirus‐resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis
por: Soponkanaporn, S., et al.
Publicado: (2018)

Anti–Cytosolic 5′‐Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis
por: Rietveld, Anke, et al.
Publicado: (2021)

What is the mortality of Juvenile Dermatomyositis (JDM) in the modern treatment era
por: Smith, S, et al.
Publicado: (2008)

Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease
por: Varsani, Hemlata, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_155io5aaumnob3cphr29prdhp1